Diagnosis of neuromyelitis spectrum disorders: Comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays

Archives of Neurology

Volumn 66, Issue 9, 2009, Pages 1134-1138

  McKeon, Andrew ^a   Fryer, James P ^a   Apiwattanakul, Metha ^a   Lennon, Vanda A ^a   Hinson, Shannon R ^a   Kryzer, Thomas J ^a   Lucchinetti, Claudia F ^a   Weinshenker, Brian G ^a   Wingerchuk, Dean M ^b   Shuster, Elizabeth A ^c   Pittock, Sean J ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN G;

ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MYELITIS; MYELOOPTIC NEUROPATHY; MYELOOPTIC NEUROPATHY SPECTRUM DISORDER; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY;

ADULT; AQUAPORIN 4; CASE-CONTROL STUDIES; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; MYELITIS, TRANSVERSE; NEUROMYELITIS OPTICA; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 70349109251     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.178     Document Type: Article

References (25)

1. Lennon VA, Lucchinetti C, Weinshenker B. Identification of a marker autoantibody of neuromyelitis optica. Neurology. 2003;60(suppl 1):A519-A520.
2. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106-2112. (Pubitemid 39626806)
3. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473-477.
4. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805-815.
5. McKeon A, Lennon VA, Lotze T, et al. CNS aquaporin-4 autoimmunity in children. Neurology. 2008;71(2):93-100.
6. Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008;70(23):2197-2200.
7. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006;59(3):566-569. (Pubitemid 43358081)
8. Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology. 2007;68(8):603-605.
9. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998;51(4):1219-1220. (Pubitemid 28473439)
10. Falcini F, Trapani S, Ricci L, Resti M, Simonini G, de Martino M. Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment. Rheumatology (Oxford). 2006;45(7):913-915. (Pubitemid 43985386)
11. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009. In press.
12. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64(7):1270-1272. (Pubitemid 40490534)
13. Capobianco M, Malucchi S, di Sapio A, et al. Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). Neurol Sci. 2007;28(4):209-211. (Pubitemid 47263843)
14. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients [published online ahead of print September 8, 2008]. Arch Neurol. 2008;65(11):1443-1448.
15. Nakashima I, Fujihara K, Miyazawa I, et al. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry. 2006;77(9):1073-1075. (Pubitemid 44338534)
16. Takahashi T, Fujihara K, Nakashima I, et al. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med. 2006;210(4):307-313. (Pubitemid 44883971)
17. Jarius S, Franciotta D, Bergamaschi R, et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology. 2007;68(13):1076-1077.
18. Marignier R, De Seze J, Durand-Dubief F, et al. NMO-IgG: a French experience. Mult Scler. 2006;12:S4.
19. Waters P, Jarius S, Littleton E, et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol. 2008;65(7):913-919. (Pubitemid 352008474)
20. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485-1489.
21. Apiwattinakul M, McKeon A, Fryer JP, Hinson SR, Pittock SJ, Lennon VA. AQP4-IgG immunoprecipitation assay optimization [letter]. Clin Chem. 2009;55(3):592-594.
22. Harper R, Reeves B. Reporting of precision of estimates for diagnostic accuracy: a review. BMJ. 1999;318(7194):1322-1323. (Pubitemid 29219045)
23. Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005;65(9):1479-1482. (Pubitemid 41552787)
24. Takahashi T, Miyazawa I, Misu T, et al. Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J Neurol Neurosurg Psychiatry. 2008;79(9):1075-1078.
25. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007;130(pt 5):1194-1205. (Pubitemid 47355941)